Genomic Testing Cooperative Opens Houston Laboratory, Expanding National Precision Oncology Network

Audio By Carbonatix

HOUSTON--(BUSINESS WIRE)--Mar 12, 2026--

Genomic Testing Cooperative (GTC), a leading provider of integrated DNA and RNA next-generation sequencing (NGS) solutions for hematologic neoplasm, solid tumors and liquid biopsy applications, today announced the opening of a new laboratory in Houston, Texas, expanding its national testing network. The 6900-square-foot facility strengthens GTC’s operational infrastructure while positioning the company within one of the world’s most significant medical and oncology research hubs. GTC will maintain its headquarters in Lake Forest, California.

Houston is home to the Texas Medical Center, the largest medical complex in the world and a global center for oncology research and clinical innovation. Establishing a laboratory presence there places GTC within an ecosystem that includes The University of Texas MD Anderson Cancer Center, Baylor College of Medicine and Texas Children’s Hospital, while expanding opportunities for collaboration with clinicians and researchers advancing precision oncology.

“Houston is one of the most important centers for oncology research and care in the world,” said Dr. Maher Albitar, Chief Executive Officer, Chief Medical Officer and Founder of GTC, who began his career in molecular diagnostics in Houston and previously held faculty positions at The University of Texas MD Anderson Cancer Center. “Returning to this ecosystem is both professionally meaningful and strategically important. By establishing a laboratory here, we can collaborate more closely with leading physicians and scientists while improving turnaround times, expanding national capacity and increasing access to high-quality genomic testing for clinicians and patients across the country.”

The Houston facility strengthens GTC’s ability to serve oncology practices, laboratories and healthcare systems nationwide by improving logistics, expanding testing capacity and reducing turnaround times for next-generation sequencing diagnostics. Its central location also adds redundancy to GTC’s national laboratory infrastructure, supporting operational continuity and faster service for customers across the United States.

The expansion also reflects GTC’s mission to expand access to advanced genomic testing through its cooperative model. Unlike traditional laboratory networks, GTC partners with other laboratories and healthcare systems (Co-Op members) sharing expertise, infrastructure and bioinformatics capabilities and them to internalize and offer high-quality molecular testing and precision medicine.

About Genomic Testing Cooperative (GTC)

GTC is a next-generation sequencing laboratory operating under a cooperative model, offering comprehensive DNA and RNA profiling for solid and hematologic malignancies, including liquid and CSF biopsies. GTC’s mission is to democratize access to advanced genomics, support innovation in precision oncology and empower labs and clinicians with high-quality molecular data. Genomictestingcooperative.com

Forward-Looking Statements

Certain statements in this press release may be forward-looking, including statements related to the presentation of data, the potential clinical impact of genomic profiling and machine-learning signatures, and GTC’s future plans. These statements involve risks and uncertainties and actual results may differ materially. GTC undertakes no obligation to update forward-looking statements unless required by law.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260312018345/en/

CONTACT: Media Contact:

Cara Stewart

WunderMarx for GTC

+1 949-290-5563

[email protected]

KEYWORD: TEXAS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY GENETICS HEALTH ONCOLOGY

SOURCE: Genomic Testing Cooperative

Copyright Business Wire 2026.

PUB: 03/12/2026 07:00 AM/DISC: 03/12/2026 07:02 AM

http://www.businesswire.com/news/home/20260312018345/en